Drug Profile
Roflumilast - AstraZeneca
Alternative Names: APTA-2217; B 9302-107; BY 217; BYK 20869; Daliresp; Daxas; IN-ALR 01; LibertekLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ALTANA Pharma
- Developer Actavis; Almirall S.A.; ALTANA Pharma; AstraZeneca; Mitsubishi Tanabe Pharma Corporation; Takeda; Takeda Pharmaceuticals International GmbH
- Class Aminopyridines; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Benzamides; Chlorinated hydrocarbons; Cyclopropanes; Fluorinated hydrocarbons; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- Discontinued Alzheimer's disease; Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis; Plaque psoriasis; Schizophrenia; Type 2 diabetes mellitus
Most Recent Events
- 27 Jul 2022 No development reported - Phase-III for Chronic obstructive pulmonary disease (Combination therapy) in Spain, United Kingdom, Austria (PO) (AstraZeneca website, July 2022) (ALTANA Pharma website, July 2022)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 23 Jul 2018 Roflumilast licensed to Acrutis Biotherapeutics worldwide for the treatment of Plaque psoriasis and Atopic dermatitis